Showing 1091-1100 of 1780 results for "".
- Virtual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® Coming Soonhttps://practicaldermatology.com/news/virtual-skin-cancer-symposium-symposium-for-inflammatory-skin-disease-coming-soon/2461166/The 2nd Annual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® (SCS + SISD) will be held virtually June 10-12, 2022. Fifteen well-known speakers will deliver 15 hours of CME credit on topics such as BCC, SCC, melanoma, actinic keratosis, dermosc
- Bill Scott Named President of Endymed's US Subsidiaryhttps://practicaldermatology.com/news/bill-scott-named-president-of-endymeds-us-subsidiary/2461151/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- PatientFi Expands Co-marketing Agreement with Allerganhttps://practicaldermatology.com/news/patientfi-expands-co-marketing-agreement-with-allergan/2461148/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an
- New AAD, Industry Collab to Increase Number of Black, Latino, and Indigenous Physicians in Dermatologyhttps://practicaldermatology.com/news/new-aad-industry-collab-to-increase-number-of-black-latino-and-indigenous-physicians-in-dermatology/2461120/The American Academy of Dermatology (AAD) in collaboration with Johnson & Johnson Consumer Health and the Janssen Pharmaceutical Companies of Johnson & Johnson is launching “Pathways: Inclusivity in Dermatology” to increase the number of practicing dermatologists in the U.S. w
- It's Grant Season: NEA Announces 2022 Eczema Research Grant Cyclehttps://practicaldermatology.com/news/its-grant-season-nea-announces-2022-eczema-research-grant-cycle-1/2461109/The National Eczema Association's (NEA) 2022 research grant cycle is now open, with awards totaling $760,000. Applications must be received by June 1, 2022, at 5 p.m. PDT, and recipients will be announced in October 2022. As the largest private nonprofi
- Vial Welcomes David Pariser, MD to its Boardhttps://practicaldermatology.com/news/vial-welcomes-david-pariser-md-to-its-board/2461105/David Pariser, MD has joined the Vial Scientific Advisory Board. The Senior Physician at Pariser Dermatology Specialists, Dr. Pariser will share the Vial CRO team and sponsors his knowledge and insights from more than 40 years as a practicing dermatologist. The
- Butt First, Endo Launches New Qwo Consumer Campaignhttps://practicaldermatology.com/news/butt-first-endo-launches-new-qwo-consumer-campaign/2461095/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United Stateshttps://practicaldermatology.com/news/leo-pharma-as-appoints-brian-hilberdink-new-president-of-leo-pharma-inc-united-states/2461084/LEO Pharma A/S appointed Brian Hilberdink as the new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022. Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.<